Clinical trials: Rituximab, completed
Lymphoma, Large Cell, Diffuse
Chemotherapy for Participants With Lymphoma
The primary purpose of this study is to help answer the following research questions: To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin (R-GEMOX) can help participants with Diffuse Large B-Cell…
- Trial name
- NCT00436280
- Testing
- enzastaurin, gemcitabine, rituximab
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Diffuse B-Cell Lymphoma
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for first-line treatment of patients with Diffuse B-Cell Large B-Cell…
- Trial name
- NCT03283202
- Testing
- Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 35 people
- Sponsor
- Celgene
Lymphoma, Large Cell, Diffuse
Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and the safety of a preparative regimen utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined with high-dose BEAM followed by ASCT…
- Trial name
- ZBEAM2 (NCT00689169)
- Testing
- ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan), ASCT, Rituximab
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Lymphoma Study Association
Lymphoma of Mucosa-Associated Lymphoid Tissue
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
The purpose of this trial is to evaluate whether a Rituximab plus 2 CdA combination therapy is effective and safe in the treatment of patients with advanced or relapsed lymphoma of the mucosa associated lymphoid tissue (MALT).
- Trial name
- NCT00656812
- Testing
- Rituximab, 2-CdA
- Where
- 5 sites in Austria
- Volunteers
- 40 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
The overall objective of this protocol is to improve the cure rate of relapsed precursor B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.
- Trial name
- NCT01700946
- Testing
- dexamethasone, vincristine sulfate, rituximab
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphocytic Leukemia, Chronic
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
This observational study will assess the therapeutic efficiency, treatment schedules, handling procedures, and the safety profile of rituximab in routine care in participants with CLL.
- Trial name
- NCT01178086
- Testing
- Rituximab
- Where
- Germany
- Volunteers
- 681 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma.
- Trial name
- NCT00655837
- Testing
- SGN-40, rituximab, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Chronic Lymphocytic Leukemia (CLL)
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
In previously-untreated subjects with CLL, fludarabine and rituximab with or without cyclophosphamide (FR or FCR) produces complete responses (CR) of 40-80%.
- Trial name
- FCR (NCT01723839)
- Testing
- Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hackensack Meridian Health
Chronic Lymphocytic Leukemia
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
This is a prospective, multicenter, open label, non-randomized, phase I/II-study to define safety and efficacy of BRL combination in relapsed/refractory patients and to recommend a safe and efficacious dose for future phase…
- Trial name
- CLL2P (NCT01558167)
- Testing
- Bendamustine, Rituximab, Lenalidomide
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- German CLL Study Group
Brain and Central Nervous System Tumors, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416819
- Testing
- filgrastim, rituximab, cytarabine
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma
In the rituximab era, one-third of diffuse large B-cell lymphoma (DLBCL) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (IChemo).
- Trial name
- NCT03664336
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
The Accuracy of Sentinel Node Biopsy of Breast Cancer With Sonographic Abnormal Axillary Lymph Nodes
This is a phase II, prospective, single-center, non-randomized, non-controlled study. Sentinel lymph node biopsy (SNB) is a standard staging procedure in early breast cancer.
- Trial name
- NCT02005926
- Testing
- Wire-localized abnormal node
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tao OUYANG
Leukemia
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
RATIONALE: Drugs used in chemotherapy, such as cladribine, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00072007
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 11 sites in Switzerland
- Volunteers
- 43 people
- Sponsor
- Swiss Cancer Institute
Follicular Lymphoma
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve…
- Trial name
- NCT02947347
- Testing
- Ibrutinib Oral Capsule, Rituximab
- Where
- 128 sites in United States, Australia and 17 more
- Volunteers
- 445 people
- Sponsor
- Pharmacyclics LLC.
MALT LYMPHOMA
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.
- Trial name
- NCT01015248
- Testing
- Rituximab and Bendamustine
- Where
- 19 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Systemic Lupus Erythematosus
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
This prospective randomized control trial is undertaken to evaluate the safety and efficacy of anti-CD20 monoclonal antibody, rituximab, used as 1. monotherapy, 2.
- Trial name
- NCT00556192
- Testing
- rituximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory…
- Trial name
- POLARGO (NCT04182204)
- Testing
- Polatuzumab Vedotin, Rituximab, Gemcitabine
- Where
- 62 sites in United States, Brazil and 14 more
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
The purpose of this research study is to learn about the safety of the treatment with a combination of bendamustine and rituximab and to find out what effects, both good and bad this treatment has on DLBCL.
- Conditions
- Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
- Trial name
- NCT01234467
- Testing
- Bendamustine, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Immune Thrombocytopenia
Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)
Aims of the study : 1) To determine whether the presence of the V158 allele of Fc gammaRIIIA gene is associated with a better outcome of Immune Thrombocytopenia (ITP) in adults and especially with a higher response-rate to…
- Trial name
- Poly-ITP (NCT02287649)
- Testing
- blood sample
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Hodgkin Lymphomas, Follicular Lymphomas
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival…
- Conditions
- Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas
- Trial name
- NCT00991211
- Testing
- Bendamustine, Standard chemotherapy CHOP + Ritiximab
- Where
- Germany
- Volunteers
- 549 people
- Sponsor
- University of Giessen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.